Skip to main content

Table 2 Details of included study arms for the estimation of effectiveness

From: Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses

Intervention

Study

Cumulative dose

Route

Duration

Day of assessment

Fraction with reduced relapse

Relapse severity (baseline EDSS)

Diagnostic criteria

High-dose methylprednisolone

Durelli 1986a [31]

7035 mgb

IV

15 days

15

10/11

5.8 (mean)

Poser 1983 [51]

Milligan 1987 [32]

2500 mg

IV

5 days

28

10/13

4.0 (median)

McDonald 1977 [52]

La Mantia 1994 [27]

5750 mg

IV

14 days

14

8/10

4.6 (mean)

McDonald 1977 [52]

Barnes 1997 [33]

3000 mg

IV

3 days

28

13/38

6.0 (median)

Not stated

Sellebjerg 1998 [34]

3676 mg

PO

15 days

21

14/26

4.5 (median)

Poser 1983 [51]

Visser 2004 [35]

2500 mgc

IV

5 days

28

6/9

3.5 (median)

Not stated

Ramo-Tello 2013 [36]

3000 mg

IV

3 days

28

15/23

4.0 (median)

McDonald 2005 [53]

Ramo-Tello 2013 [36]

3750 mg

PO

3 days

28

15/22

3.0 (median)

McDonald 2005 [53]

Low-dose methylprednisolone

Milanese 1989 [26]

390 mg

IV

14 days

30d

3/10

4.9 (mean)

McDonald 1977 [52]

La Mantia 1994 [27]

390 mg

IV

14 days

14

6/10

4.7 (mean)

McDonald 1977 [52]

Barnes 1997 [33]

588 mg

PO

21 days

28

20/42

5.0 (median)

Not stated

Placebo

Miller 1961 [37]

-

IM

21 days

21

4/18e

Not stated

Not stated

Rose 1970 [38]

-

IM

14 days

28

39.25/94f

5.2 (mean)

Rose 1968 [54]

Durelli 1986a [31]

-

IV

15 days

15

4/10

5.9 (mean)

Poser 1983 [51]

Milligan 1987 [32]

-

IV

5 days

28

2/9

4.0 (median)

McDonald 1977 [52]

Sellebjerg 1998 [34]

-

PO

15 days

21

6/25

4.0 (median)

Poser 1983 [51]

  1. IV intravenous, PO per oral, IM intramuscular
  2. a Only the 15 days controlled period of this trial is considered here
  3. b Based on a weight of 70 kg
  4. c Patients also received 2 % human albumin
  5. d This study lacked reported assessments in the 14–28 day interval
  6. e No EDSS measurement performed; the result refers to the fraction with an ‘undoubted response to treatment’
  7. f Conversion based on the assumption that a DSS of e.g. 4 is equally likely to correspond to EDSS 4.0 as EDSS 4.5